Leadership
JPM 2020 l The changing landscape of global healthcare in the new decade
I was struck by a resounding shift in attitude at this year’s J.P. Morgan Healthcare Conference; less talk, more action. The atmosphere felt more...
Life science talent in China’s booming life science sector
Whatever statistics one reads about China, they never fail to impress with their scale and rate of growth. In 2007, China was the world’s...
Private sector IR35 update on the horizon yet in change lies opportunity
Interim Management is the means by which an individual provides professional services to a client-base of their choosing. It is typically delivered by highly...
IQ might get you hired but EQ will get you promoted
The rise of EQ is interesting because it goes hand in hand with technological and sociological evolution. 20-30 years ago, leaders were sought (predominately)...
Who can put a price on cell and gene therapy?
Insights from the Endpoints UK Biotech Summit October 2019 Fifteen years ago, Health Economics Outcomes Research (HEOR) was the pharma industry’s new kid on...
RSA Talent Talks debut Podcast
We’re seeing some of the most exciting new therapeutics emerge from the Cell & Gene Therapy Sector, it’s happening quickly and delivering meaningful results...
Anyone for T?
The increasing demand for highly specialised skill sets in drug development Do employers prefer specialists or generalists? While many would answer ‘it depends’, the...
Making the leap into self-employment? Don’t be an interim lemming
Deciding to work for yourself is a big leap of faith and varies considerably from the well-trodden path of employment. So, it pays to...
JPM 2019 |The fundamentals remain strong despite the doubters
I’ve taken longer than usual to write my JPM blog this year. It was a week when there was such a division of opinion...
Launching your first medical product in Europe? How not to fail at the first step
So, you have your first product close to launch or are even on the market in the U.S. You’re planning to take it to...
Bringing fresh talent into the Alzheimer’s space
It’s more than 15 years since the pharmaceutical industry succeeded in launching a new drug to treat Alzheimer’s disease. Since then, over 99% of...
Solving the life sciences talent puzzle in Asia
Living and working in the Asia-Pacific region for the past 7 years has given me a close-up view of the fast growth of its...
Who guards the Guards in life science companies?
This isn’t a new question; it’s been asked by every civilisation, from the Greeks on holding people in power to account, and the Romans...
Outlook: Medtech 2030
Having travelled in Europe in the last few weeks meeting clients and candidates, I wanted to share some reflections with you linked to one...
Finding talent for late stage neuroscience drug development
At a recent OBN/One Nucleus BioTuesday focusing on neurodegenerative diseases, I heard again the extent of the challenge faced by scientists wanting to develop...
Efficient engagement with executive search
When looking for a new role, you’ll have plenty of questions for a potential new employer. Ahead of any interview, you’ll do your due...
Lateral thinking for oncology leadership
The rapid growth in immuno-oncology therapeutics is causing talent headaches for the pharma industry Patients are already benefitting from pharma’s success in developing new...
The UK is a leader in life sciences. How can we make sure that it remains No.1 in Europe?
After spending a day in mid-October at this year’s excellent UK BioScience Forum, I was left with one particular thought ringing loud and clear...